Wang Erin Y, Phipps Rebecca, Dean Stephanie A, Li Ling, Nestadt Danielle, Nestadt Paul S
Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Office of the Chief Medical Examiner, Baltimore, MD, USA.
Drug Alcohol Depend. 2025 Mar 1;268:112553. doi: 10.1016/j.drugalcdep.2025.112553. Epub 2025 Jan 28.
Xylazine is a fentanyl contaminant which has been increasingly detected in drug overdose deaths in Maryland. This study explored risk factors and time trends of xylazine-related overdose deaths (XRODs) in Maryland from 2020 to 2023.
This serial cross-sectional study utilized data from the Maryland Office of the Chief Medical Examiner on fentanyl overdose deaths that occurred from 2020 to 2023. XROD was defined as someone who died from overdose and had a positive postmortem blood xylazine test. Multivariable logistic regression modeled associations between demographic variables and presence of co-occurring substances with XROD. Annual population-based XROD rates were calculated for the overall sample and by race, age group, and sex.
There were 8721 fentanyl overdose deaths in Maryland between 2020 and 2023. Among these, 1798 (20.6 %) were XRODs. Annual XROD rates peaked in 2021 and have declined since then. Although Black Marylanders experienced the highest overall burden of overdose, xylazine was significantly more likely to contribute to fentanyl overdose deaths among White individuals compared to Black individuals (aOR 1.18) and those aged 31-40 years compared to those 60 or older (aOR 1.25). Morphine (aOR 1.36), methadone (aOR 1.41), benzodiazepines (aOR 1.20), and tramadol (aOR 2.12) were associated with higher odds of XROD.
XRODs are a major problem in Maryland, and there are significant differences in XROD mortality by race, age, and co-occurring substance use. Efforts to reduce xylazine-related mortality in Maryland should provide overdose prevention education and harm reduction services to the most vulnerable populations.
赛拉嗪是一种芬太尼污染物,在马里兰州药物过量死亡案例中越来越多地被检测到。本研究探讨了2020年至2023年马里兰州与赛拉嗪相关的过量死亡(XROD)的风险因素和时间趋势。
这项系列横断面研究利用了马里兰州首席法医办公室提供的2020年至2023年芬太尼过量死亡数据。XROD定义为因过量用药死亡且死后血液赛拉嗪检测呈阳性的人。多变量逻辑回归模型分析了人口统计学变量和同时存在的物质与XROD之间的关联。计算了总体样本以及按种族、年龄组和性别划分的基于人群的年度XROD率。
2020年至2023年期间,马里兰州有8721例芬太尼过量死亡案例。其中,1798例(20.6%)为XROD。年度XROD率在2021年达到峰值,此后有所下降。尽管马里兰州黑人经历的过量用药总体负担最高,但与黑人相比,赛拉嗪导致白人芬太尼过量死亡的可能性显著更高(调整后比值比为1.18),与60岁及以上人群相比,31至40岁人群中赛拉嗪导致芬太尼过量死亡的可能性显著更高(调整后比值比为1.25)。吗啡(调整后比值比为1.36)、美沙酮(调整后比值比为1.41)、苯二氮䓬类药物(调整后比值比为1.20)和曲马多(调整后比值比为2.12)与XROD的较高几率相关。
XROD在马里兰州是一个主要问题,XROD死亡率在种族、年龄和同时使用的物质方面存在显著差异。马里兰州为降低与赛拉嗪相关的死亡率所做的努力应向最脆弱人群提供过量用药预防教育和减少伤害服务。